Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» In a stunning setback, Roche says its top cancer drug Tecentriq failed a key PhIII study
In a stunning setback, Roche says its top cancer drug Tecentriq failed a key PhIII study
In a stunning setback, Roche says its top cancer drug Tecentriq failed a key PhIII study
Submitted by
admin
on May 10, 2017 - 10:13am
Source:
Endpoints
News Tags:
Roche
Tecentriq
clinical trials
bladder cancer
Headline:
In a stunning setback, Roche says its top cancer drug Tecentriq failed a key PhIII study
Do Not Allow Advertisers to Use My Personal information
